查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618657

微生物組診斷市場：按產品類型、應用和最終用戶分類 - 全球預測 2025-2030

Microbiome Diagnostics Market by Product Type (Instruments, Reagents & Kits), Application (Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年微生物組診斷市值為7.9936億美元，預計到2024年將達到9.6027億美元，複合年成長率為20.72%，預計到2030年將達到29.8787億美元。

微生物組診斷專注於分析人類和其他宿主微生物群落的遺傳物質，以診斷健康狀況並徹底改變個人化醫療。人們越來越認知到微生物組在健康和疾病中發揮的作用，推動了這個市場的需求，微生物組有助於胃腸道、代謝和免疫疾病等領域的早期檢測、監測和治療，我們支持個體化治療。其應用涵蓋醫療保健、製藥、農業和生物技術，最終用途為醫院、診斷實驗室、研究機構和專科診所。市場開拓是由研究和開發活動的活性化、慢性病患病率的上升以及人們對微生物組在健康中所發揮的重要作用的認知不斷提高所推動的。政府投資以及學術機構和生物技術公司之間的合作正在進一步推動進展。然而，市場面臨著高測試成本、道德考慮、監管障礙和資料隱私問題等挑戰，這可能會阻礙成長。理解複雜的微生物與宿主相互作用以及將研究轉化為臨床實踐的限制帶來了額外的挑戰。儘管存在這些障礙，但擴大微生物組診斷在精準醫學中的應用、開發非侵入性檢測方法以及整合人工智慧進行資料分析仍然存在重大機會。公司可以開拓醫療保健基礎設施正在發展且醫療需求未開拓領域。創新開發具有成本效益的快速診斷工具並專注於消費者教育宣傳活動將有助於提高市場接受度。該市場本質上是動態的，其特點是快速的技術進步以及活躍的新興企業和老牌公司的競爭格局。公司可以透過專注於協作研究、多組體學方法和提供全面的微生物組分析服務來取得成功。這個快速發展的產業需要敏捷性和警覺性，以利用策略夥伴關係和突破性技術。

主要市場統計
基準年[2023] 7.9936 億美元
預計年份 [2024] 9.6027億美元
預測年份 [2030] 2,987,870,000 美元
複合年成長率（%） 20.72%

市場動態：揭示快速發展的微生物組診斷市場的關鍵市場洞察

供需的動態交互作用正在改變微生物組診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率上升以及微生物組診斷劑的重要性
    • 政府對微生物組研究的措施與支持
  • 市場限制因素
    • 缺乏微生物組診斷的報銷政策
  • 市場機會
    • 增加微生物組研究的投資
    • 微生物組診斷在個人化治療開發的潛力不斷成長
  • 市場挑戰
    • 缺乏針對微生物組的標準化通訊協定和可用療法

波特的五力：駕馭微生物組診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解微生物組診斷市場的外部影響

外部宏觀環境因素在塑造微生物組診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解微生物組診斷市場的競爭格局

對微生物組診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣微生物組診斷市場供應商的績效評估

FPNV定位矩陣是評估微生物組診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪微生物組診斷市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，微生物組診斷市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病盛行率上升以及基於微生物組的診斷的重要性
      • 政府對微生物組研究的措施與支持
    • 抑制因素
      • 缺乏基於微生物組的診斷的報銷政策
    • 機會
      • 增加微生物組研究的投資
      • 微生物組診斷在開發個人化治療方法的潛力不斷成長
    • 任務
      • 缺乏針對微生物組的標準化通訊協定和可用治療方法
  • 市場區隔分析
    • 產品類型：需要能夠處理複雜分析的準確且有效率的設備。
    • 最終用戶：製藥和生物技術公司更多地採用微生物組診斷來開發個人化治療方法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章微生物組診斷市場：依產品類型

  • 裝置
  • 試劑和套件

第7章微生物組診斷市場：依應用分類

  • 胃腸道疾病
  • 感染疾病
  • 代謝紊亂

第 8 章微生物組診斷市場：依最終用戶分類

  • 製藥和生物技術公司
  • 研究/學術機構

第9章美洲微生物組診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太微生物組診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的微生物組診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 推出目標微生物組分析，這是一種針對健康和疾病的基於途徑的微生物組分析服務
    • Evvy 是一家專注於陰道微生物組的精準女性健康Start-Ups，宣布獲得 1,400 萬美元 A 輪資金籌措
    • Xume 與 Microbiome.in 和 TruDiagno 合作，幫助人們根據腸道微生物組做出選擇。
  • 戰略分析和建議

公司名單

  • 4D Pharma PLC
  • AOBiome Therapeutics
  • Atlas Biomed
  • BioGaia
  • BIOHM Health
  • Bione Ventures Private Limited
  • DayTwo
  • DNA Genotek Inc. by OraSure Technologies Inc.
  • Du Pont De Nemours and Co.
  • Enterome
  • Evvy
  • Ferring Pharmaceuticals
  • Finch Therapeutics Group
  • Flightpath Biosciences, Inc.
  • Genetic Analysis AS
  • Gnubiotics Sciences
  • International Flavors & Fragrances Inc
  • Luxia Scientific
  • MEtabiomics
  • Microba Life Sciences
  • OptiBiotix Health PLC
  • Osel Inc.
  • Quantbiome, Inc.
  • Rebiotix
  • Second Genome, Inc.
  • Seed Health
  • Seres Therapeutics
  • Sun Genomics
  • Symbiotix Biotherapies,
  • Synlogic, Inc.
  • Synthetic Biologics
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc.
  • ViThera
  • ViThera Pharmaceuticals, Inc.
  • Yakult Honsha Co.
  • YSOPIA Bioscience
Product Code: MRR-BF5906741E57

The Microbiome Diagnostics Market was valued at USD 799.36 million in 2023, expected to reach USD 960.27 million in 2024, and is projected to grow at a CAGR of 20.72%, to USD 2,987.87 million by 2030.

Microbiome diagnostics focuses on analyzing the genetic material of microbial communities in human and other hosts to diagnose health conditions, offering a revolution in personalized medicine. This market's necessity stems from the growing recognition of the microbiome's role in health and disease, where it aids in early detection, monitoring, and treatment personalization in areas like gastrointestinal, metabolic, and immune disorders. Its applications span healthcare, pharmaceuticals, agriculture, and biotechnology, with end-uses in hospitals, diagnostic labs, research institutions, and specialty clinics. Market growth is driven by increasing research and development activities, the rising prevalence of chronic diseases, and growing awareness of the microbiome's critical health roles. Government investments and collaborations between academic institutions and biotech companies further bolster advancements. However, the market faces challenges such as high testing costs, ethical considerations, regulatory hurdles, and data privacy concerns that may impede growth. Limitations in understanding the complex microbiome-host interactions and translating research into clinical practice pose additional challenges. Despite these hurdles, substantial opportunities exist in expanding the application of microbiome diagnostics in precision medicine, developing non-invasive testing methods, and integrating artificial intelligence for data analysis. Companies can tap into unexplored regions with rising healthcare infrastructure and unmet medical needs. Innovating in developing cost-effective, rapid diagnostic tools and emphasizing consumer awareness campaigns could drive wider market acceptance. The market is inherently dynamic, marked by rapid technological advancements and a competitive landscape with active start-ups and established players. Businesses can succeed by focusing on collaborative research, multi-omic approaches, and offering comprehensive microbiome profiling services. This rapidly evolving sector demands agility and vigilance to capitalize on aimed strategic partnerships and breakthrough technologies.

KEY MARKET STATISTICS
Base Year [2023] USD 799.36 million
Estimated Year [2024] USD 960.27 million
Forecast Year [2030] USD 2,987.87 million
CAGR (%) 20.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Microbiome Diagnostics Market

The Microbiome Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases and significance of microbiome-based diagnostics
    • Government initiatives and support for microbiome research
  • Market Restraints
    • Lack of reimbursement policies for microbiome-based diagnostics
  • Market Opportunities
    • Increasing investment in microbiome-based research
    • Growing potential of microbiome diagnostics in developing personalized treatments
  • Market Challenges
    • Lack of standardized protocols and available therapeutics targeting the microbiome

Porter's Five Forces: A Strategic Tool for Navigating the Microbiome Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Microbiome Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Microbiome Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Microbiome Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Microbiome Diagnostics Market

A detailed market share analysis in the Microbiome Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Microbiome Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Microbiome Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Microbiome Diagnostics Market

A strategic analysis of the Microbiome Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Microbiome Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Pharma PLC, AOBiome Therapeutics, Atlas Biomed, BioGaia, BIOHM Health, Bione Ventures Private Limited, DayTwo, DNA Genotek Inc. by OraSure Technologies Inc., Du Pont De Nemours and Co., Enterome, Evvy, Ferring Pharmaceuticals, Finch Therapeutics Group, Flightpath Biosciences, Inc., Genetic Analysis AS, Gnubiotics Sciences, International Flavors & Fragrances Inc, Luxia Scientific, MEtabiomics, Microba Life Sciences, OptiBiotix Health PLC, Osel Inc., Quantbiome, Inc., Rebiotix, Second Genome, Inc., Seed Health, Seres Therapeutics, Sun Genomics, Symbiotix Biotherapies,, Synlogic, Inc., Synthetic Biologics, Vedanta Biosciences, Inc., Viome Life Sciences, Inc., ViThera, ViThera Pharmaceuticals, Inc., Yakult Honsha Co., and YSOPIA Bioscience.

Market Segmentation & Coverage

This research report categorizes the Microbiome Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments and Reagents & Kits.
  • Based on Application, market is studied across Gastrointestinal Disorders, Infectious Diseases, and Metabolic Disorders.
  • Based on End-user, market is studied across Pharmaceutical & Biotechnology Companies and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and significance of microbiome-based diagnostics
      • 5.1.1.2. Government initiatives and support for microbiome research
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement policies for microbiome-based diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in microbiome-based research
      • 5.1.3.2. Growing potential of microbiome diagnostics in developing personalized treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardized protocols and available therapeutics targeting the microbiome
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Need for accurate and efficient instruments capable of handling complex analyses
    • 5.2.2. End-user: Growing adoption of microbiome diagnostics in pharmaceutical and biotechnology companies to develop personalized therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Microbiome Diagnostics Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Kits

7. Microbiome Diagnostics Market, by Application

  • 7.1. Introduction
  • 7.2. Gastrointestinal Disorders
  • 7.3. Infectious Diseases
  • 7.4. Metabolic Disorders

8. Microbiome Diagnostics Market, by End-user

  • 8.1. Introduction
  • 8.2. Pharmaceutical & Biotechnology Companies
  • 8.3. Research & Academic Institutes

9. Americas Microbiome Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Microbiome Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Microbiome Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Launch of "Targeted Microbiome Profiling", a pathway-based microbiome profiling service for health and disease
    • 12.3.2. Evvy, Precision Women's Health Startup focused on the Vaginal Microbiome, Announces USD 14 million Series A
    • 12.3.3. Xume partners with Microbiome.in and TruDiagno to help people make gut microbiome-informed choices
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Pharma PLC
  • 2. AOBiome Therapeutics
  • 3. Atlas Biomed
  • 4. BioGaia
  • 5. BIOHM Health
  • 6. Bione Ventures Private Limited
  • 7. DayTwo
  • 8. DNA Genotek Inc. by OraSure Technologies Inc.
  • 9. Du Pont De Nemours and Co.
  • 10. Enterome
  • 11. Evvy
  • 12. Ferring Pharmaceuticals
  • 13. Finch Therapeutics Group
  • 14. Flightpath Biosciences, Inc.
  • 15. Genetic Analysis AS
  • 16. Gnubiotics Sciences
  • 17. International Flavors & Fragrances Inc
  • 18. Luxia Scientific
  • 19. MEtabiomics
  • 20. Microba Life Sciences
  • 21. OptiBiotix Health PLC
  • 22. Osel Inc.
  • 23. Quantbiome, Inc.
  • 24. Rebiotix
  • 25. Second Genome, Inc.
  • 26. Seed Health
  • 27. Seres Therapeutics
  • 28. Sun Genomics
  • 29. Symbiotix Biotherapies,
  • 30. Synlogic, Inc.
  • 31. Synthetic Biologics
  • 32. Vedanta Biosciences, Inc.
  • 33. Viome Life Sciences, Inc.
  • 34. ViThera
  • 35. ViThera Pharmaceuticals, Inc.
  • 36. Yakult Honsha Co.
  • 37. YSOPIA Bioscience

LIST OF FIGURES

  • FIGURE 1. MICROBIOME DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MICROBIOME DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MICROBIOME DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MICROBIOME DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023